IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

tebentafusp-tebn injection

tebentafusp-tebn injection
for intravenous use Initial U.S. Approval: 2022

Kimmtrak (tebentafusp-tebn) is a medication used to treat unresectable or metastatic uveal melanoma, an aggressive cancer of the eye.

Facts about tebentafusp-tebn injection

Approval Date: 1/25/2022
Proprietary Name: Kimmtrak
Active Ingredient(s): tebentafusp-tebn
FDA-approved use: To treat unresectable or metastatic uveal melanoma
Dosage Form: Injection
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “tebentafusp-tebn injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For tebentafusp-tebn injection

Approved accessible "tebentafusp-tebn injection"

Kimmtrak (tebentafusp-tebn) injection is the first therapy for metastatic or unresectable uveal melanoma, a rare cancer that develops in a part of the eye called the uvea.

Tebentafusp is indicated for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer). Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. Tebentafusp was approved for medical use in the United States in January 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication

How can 1 go about obtaining tebentafusp-tebn injection?

If tebentafusp-tebn injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

Kimmtrak (tebentafusp-tebn) injection for intravenous use Initial U.S. Approval: 2022

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398